ReviewAmerican journal of neurodegenerative disease2025
The role of nuclear medicine in neurodegenerative diseases: a narrative review.
Review in American journal of neurodegenerative disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Limited predictive value of preoperative nigrosome integrity for motor outcomes in Parkinson's disease deep brain stimulation.NPJ Parkinson's disease · 2025Article
- Deep Learning-Based Assessment of Brainstem Volume Changes in Spinocerebellar Ataxia Type 2 (SCA2): A Study on Patients and Preclinical Subjects.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Lewy body dementia, are associated with the accumulation of brain proteins, leading to neuroinflammation, disruption of cellular clearance mechanisms, and neuronal death. Nuclear medicine, utilizing technologies like PET and SPECT, plays a crucial role in diagnosing and managing these disorders. Recent advancements in nuclear medicine have enhanced the understanding of disease pathophysiology and facilitated the development of tailored therapeutics. This study aims to address gaps in understanding nuclear medicine's potential to improve early diagnosis, monitor disease progression, and evaluate therapeutic effectiveness. In this review, we analyzed 28 papers and summarized their findings. PET radioligands have revolutionized the in vivo measurement of pathological targets in neurological diseases, offering new insights into the pathophysiology of neurodegenerative conditions. Amyloid PET has emerged as a reliable diagnostic imaging tool, accurately identifying cerebral amyloid-beta accumulation and enabling early differential diagnosis in clinical settings. Furthermore, radiopharmaceuticals such as [18F]Flortaucipir, [18F]FDOPA, and TSPO ligands provide significant advancements in the diagnosis and treatment of neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.